TotalCareMedical.com

Weighing a supplement or telehealth program? Evidence and label checks come first

TotalCareMedical.com Health Team

MadeMed Oral Semaglutide vs. Injectable GLP-1: What the Evidence Says in 2026

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important: Compounded GLP-1 medications discussed in this article are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This content is for educational and informational purposes only. All prescription decisions are made by licensed healthcare providers. Consult your provider before starting any prescription medication.

One of the most common questions prospective patients ask about GLP-1 telehealth programs right now is whether the oral format actually works — and whether it's worth choosing over an injectable. MadeMed offers both, starting at $99 per month for oral semaglutide and also offering injectable semaglutide and both oral and injectable tirzepatide. This article breaks down what the research actually supports, what “oral semaglutide” means in the telehealth context, and how to think about the format decision from an evidence standpoint.

Clinical Summary: GLP-1 Formulation Comparison (Oral vs. Injectable)

Topic: Telehealth GLP-1 medications — oral semaglutide, injectable semaglutide, and tirzepatide formats
Key Active Ingredients: Semaglutide (FDA-approved injectable and oral forms; compounded sublingual); tirzepatide (oral and injectable)
Price Range: Starting at $99/month for oral semaglutide through MadeMed; injectable and tirzepatide options available at higher tiers
Evidence Level: Injectable semaglutide has strongest phase 3 trial evidence (STEP program); compounded sublingual semaglutide lacks equivalent clinical trial data; FDA-approved oral semaglutide (Rybelsus, Wegovy) completed phase 3 evaluation
Best For: Patients seeking GLP-1 therapy who need to understand the pharmacological differences between FDA-approved and compounded formulations before making an informed treatment choice with their provider
Caution: Compounded sublingual semaglutide is not FDA-approved and bioavailability cannot be assumed equivalent to injectable or FDA-approved oral forms; requires empty stomach and specific administration timing; consult licensed provider before starting any GLP-1 medication

What “Oral Semaglutide” Actually Means in 2026

The term “oral GLP-1” covers at least four meaningfully different things in the current market, and conflating them produces bad decisions. Understanding the distinctions is the most important thing this article can offer.

FDA-approved oral semaglutide includes two products: Rybelsus, a daily swallowed tablet approved for type 2 diabetes management, and the oral Wegovy formulation that launched in late 2025 for weight management. Both have completed phase 3 clinical trial programs evaluating their efficacy, safety, and pharmacokinetics as finished drug products. They require specific administration conditions — typically an empty stomach, small amount of water, and a waiting period before eating — because oral bioavailability of semaglutide is inherently challenging due to its peptide structure and susceptibility to gastric degradation.

Compounded sublingual semaglutide — the format available through MadeMed and most other GLP-1 telehealth platforms — is a separate category. These are compounding pharmacy formulations that dissolve under the tongue rather than being swallowed. The mechanism bypasses initial gastric transit by relying on sublingual absorption through the mucous membranes. This is a pharmacologically coherent delivery route. However, compounded sublingual semaglutide has not been evaluated in equivalent phase 3 human clinical trials. The bioavailability, pharmacokinetic profile, and clinical outcomes of these formulations cannot be assumed to match those of either FDA-approved injectable semaglutide or FDA-approved oral semaglutide based on preclinical or theoretical arguments alone.

This isn't a reason to dismiss the format — it's a reason to understand what you're actually choosing. For a detailed review of how MadeMed structures its programs across all GLP-1 formats, see our full MadeMed platform review.

What the Injectable Evidence Base Establishes

Injectable semaglutide has the strongest and most established evidence base of any semaglutide formulation. The STEP trial program, published in peer-reviewed literature including the New England Journal of Medicine, studied once-weekly subcutaneous semaglutide at 2.4mg in adults with obesity combined with lifestyle intervention. The STEP 1 trial found clinically meaningful average body weight reduction in the treatment group versus placebo after 68 weeks. These are the trials that established the clinical rationale for GLP-1 therapy in weight management — and they used injectable, FDA-approved branded semaglutide under controlled trial conditions.

Compounded injectable semaglutide — the format also available through MadeMed — uses the same active ingredient (semaglutide) administered the same way (subcutaneous injection), but is a compounded formulation rather than an FDA-approved finished drug. The pharmacological mechanism is the same, but the regulatory status, quality control standards, and evidence basis for the specific compounded formulation differ. Compounded medications are not evaluated by the FDA for safety, efficacy, or quality control before they are dispensed.

The Oral Semaglutide Clinical Picture: What Phase 3 Data Shows for FDA-Approved Formats

The oral Wegovy clinical program (OASIS trials) evaluated swallowed oral semaglutide at 50mg once daily in adults with obesity. Published results demonstrated meaningful weight reduction compared to placebo, though average weight loss figures were somewhat lower than those observed in the injectable STEP trials. These results establish proof of concept for oral semaglutide as a clinically effective approach — but again, these are trials of an FDA-approved finished drug product, not of compounded sublingual tablets.

The mechanistic argument for sublingual absorption is that it bypasses the gastric degradation challenge that makes oral peptide delivery difficult. Whether compounded sublingual semaglutide achieves clinically meaningful systemic exposure in practice — and at what doses — is not established by published phase 3 human trial data as of this writing. This is a genuine evidence gap, not a disqualifying flaw. Clinicians prescribe medications through compounding when the individual patient's needs support it. But patients deserve to know that the “oral semaglutide” available through telehealth platforms is not the same product, and does not have the same evidence base, as the oral Wegovy pill that launched in late 2025.

How MadeMed's Oral Semaglutide Pricing Compares to the Market

At a published starting price of $99 per month, MadeMed's oral semaglutide sits at the lower end of the compounded telehealth market for this format. For context, oral semaglutide sublingual tablets from other platforms are priced higher: the SynergyRx oral dissolving tablet program starts at $299 per month for semaglutide per publicly available information, while programs reviewed on this site, including FuturHealth and Remote Pharmacy, structure their pricing differently, with injectable-focused programs in comparable ranges.

The key pricing consideration that every prospective patient should apply: compare total cost at maintenance dose, not starting price. GLP-1 programs titrate upward over months. The $99 entry point applies to the lowest starting dose of oral semaglutide — the dose at which most clinical protocols begin before gradually increasing. As dose increases, price increases. The monthly cost at a therapeutic maintenance dose will be higher than the published starting price. Verify the full pricing tier structure directly on mademed.com before enrolling.

For the FDA-approved oral alternative: Novo Nordisk has published self-pay pricing for oral Wegovy at $149 per month for certain dose tiers through its manufacturer direct program. For patients who qualify and prefer an FDA-approved finished drug, the price differential between compounded sublingual semaglutide and the approved oral pill has narrowed significantly in 2026. This is a conversation to have with your prescribing clinician — not a decision to make based on cost alone, since eligibility, insurance, and individual medical history all factor in.

How to Think About the Format Decision

The right format — oral or injectable — is a clinical decision, not a marketing decision. A few questions worth discussing with your provider: Do you have any medical reason to avoid subcutaneous injections? Does your state's prescribing regulations or the platform's clinical protocols affect which formats are available to you? Is there a compounded tirzepatide option worth considering if semaglutide isn't the right fit? Are you looking for an FDA-approved finished drug product specifically, or are you open to a compounded formulation under medical supervision?

MadeMed offers the flexibility of both formats across two GLP-1 molecules (semaglutide and tirzepatide), which is a genuine differentiator compared to platforms that offer only one format or one molecule. Whether that flexibility translates to better outcomes for any individual patient is a question for their licensed clinician. This topic connects to what we cover in MadeMed Tirzepatide Review 2026: Compounded GLP-1/GIP Therapy, Pricing, and What to Know.

Frequently Asked Questions

Is oral semaglutide as effective as injectable semaglutide?

FDA-approved oral semaglutide (Rybelsus and oral Wegovy) has been studied in clinical trials and demonstrates meaningful weight reduction, though phase 3 trial data generally shows somewhat less average weight loss compared to injectable semaglutide at equivalent doses. Compounded sublingual semaglutide tablets — the format available through most telehealth platforms — have not been evaluated in equivalent phase 3 human trials. The bioavailability and clinical outcomes of compounded sublingual formats cannot be assumed to be equivalent to either FDA-approved injectable or FDA-approved oral semaglutide products.

Why is MadeMed's oral semaglutide priced lower than competitors?

MadeMed's published starting price for oral semaglutide ($99/month at the lowest dose) positions it at the lower end of the compounded telehealth market. Pricing differences between telehealth platforms reflect differences in pharmacy sourcing, bundled services, dose tier structures, and membership models. Lower starting price does not always reflect lower total cost at maintenance dose. Prospective patients should compare total monthly cost at their expected therapeutic dose, not just entry-level pricing.

What is the difference between compounded sublingual semaglutide and oral Wegovy?

Oral Wegovy is an FDA-approved finished drug product that has completed phase 3 clinical trials evaluating its safety, efficacy, and bioavailability as a swallowed tablet. Compounded sublingual semaglutide — the format available through telehealth platforms including MadeMed — is a compounding pharmacy formulation that dissolves under the tongue. It uses semaglutide as an active ingredient but is not FDA-approved and has not been evaluated in equivalent human clinical trials. The two formats have different regulatory statuses and different evidence bases.

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

MadeMed Review 2026: GLP-1 Telehealth Platform, Pricing, and What Patients Should Know

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important: MadeMed is a telehealth platform that facilitates access to prescription medications. It does not provide direct medical care. All prescribing decisions are made by licensed clinicians affiliated with Xpedicare, LLC, an independent medical group. Compounded medications dispensed through this platform are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This review is for informational and educational purposes only. Consult your healthcare provider before starting any prescription treatment.

The compounded GLP-1 telehealth market has expanded to dozens of platforms in the last two years, and most of what you'll find when you search for reviews falls into one of two failure modes: promotional content that reads like a sales page, or vague skepticism that doesn't tell you anything specific. This review does neither. We examined MadeMed's public-facing website, its Terms of Use, third-party verification sources, and the broader regulatory environment around compounded semaglutide to give you a research-level breakdown of what this platform actually offers — and what you need to verify before enrolling.

Clinical Summary: MadeMed GLP-1 Telehealth Platform

Category: Telehealth Platform for Prescription Medications
Key Active Medications Offered: Injectable semaglutide, injectable tirzepatide, compounded oral semaglutide, compounded oral tirzepatide
Price Range: Starting at $149
Evidence Level: Compounded GLP-1 formulations lack FDA approval and phase 3 human trial data for safety and efficacy, distinguishing them from FDA-approved alternatives.
Best For: Patients seeking telehealth access to GLP-1 medications for weight loss who have consulted with their healthcare provider.
Caution: Compounded medications are not FDA-approved; platform does not provide direct medical care; verify provider credentials and consult your healthcare provider before enrollment.

What Is MadeMed?

MadeMed is an online telehealth platform operated by IDL Health LLC, headquartered in Houston, Texas. The platform connects patients with licensed medical providers affiliated with Xpedicare, LLC, an independent medical group that is solely responsible for clinical services and all prescribing decisions. MadeMed holds LegitScript certification, an independent verification standard that evaluates online healthcare companies for legal compliance, safety, and transparency. Medication is dispensed through AbsoluteRx, a licensed pharmacy partner.

The platform operates across four clinical categories: GLP-1 weight loss programs, men's sexual health, peptide therapy, and NAD+ therapy. For most prospective patients, the GLP-1 weight-loss programs are the primary focus—and that's where the majority of this review is concentrated.

MadeMed GLP-1 Programs: What the Platform Offers

MadeMed offers four GLP-1 medication formats. Injectable semaglutide and injectable tirzepatide are the traditional subcutaneous injection options administered once weekly. Oral semaglutide and oral tirzepatide are compounded sublingual tablet formulations that dissolve under the tongue — a needle-free alternative that has grown significantly in market share among telehealth GLP-1 platforms in 2025 and 2026.

It's worth being specific about what “oral semaglutide” means in this context. The compounded sublingual tablets available through MadeMed and most telehealth platforms differ from the FDA-approved oral semaglutide products that have reached the market — specifically Rybelsus (the original oral tablet) and the oral Wegovy formulation launched in late 2025. Compounded sublingual semaglutide is not an FDA-approved finished drug and has not been evaluated in phase 3 human trials for efficacy or bioavailability under the same conditions as the approved oral formulations. For a more detailed breakdown of the oral format landscape, see our comparison of oral GLP-1 telehealth programs.

MadeMed Pricing: What the Published Numbers Actually Mean

Based on publicly available information as of May 2026, MadeMed's oral semaglutide program starts at $99 per month at the lowest dose tier. Pricing increases as doses are titrated upward throughout treatment. NAD+ nasal spray is listed at up to $269 per month at higher tiers. An optional MadeMed Club membership, priced at $149 per year, provides a $10 monthly discount across the platform's programs.

A few pricing realities worth understanding before you commit. First, the starting price is almost never the price you'll actually pay at a therapeutic maintenance dose. GLP-1 programs begin at the lowest titration dose — typically 0.25mg for semaglutide — and increase over months based on individual response and tolerability. The per-month cost typically increases with dose. Second, subscription billing is automatic. MadeMed's Terms of Use state that services are offered on a recurring subscription basis and that the platform does not offer prorated refunds. Cancellation is available via email to support@mademed.com or through the account portal and takes effect at the end of the current billing period. Read those terms before you enter payment information.

For context on how MadeMed's pricing compares to other compounded GLP-1 platforms in the current market, see our analysis of the MEDVi GLP-1 program, which starts at $179 per month for injectable semaglutide, and our review of SynergyRx GLP-1, which offers oral dissolving tablet options starting at $299 per month for semaglutide. At its published starting price, MadeMed's oral semaglutide option sits at the lower end of the compounded telehealth market.

Regulatory Context: Compounded Medications and the 2025-2026 Enforcement Environment

This section matters more in 2026 than it would have two years ago, and anyone considering a compounded GLP-1 program should understand it clearly.

Compounded medications are patient-specific formulations prepared by licensed compounding pharmacies. They are legal and widely prescribed, but they are not FDA-approved finished drugs. The FDA does not evaluate compounded medications for safety, efficacy, or quality control before they are dispensed. MadeMed's Terms of Use state this explicitly: “Compounded drugs are not approved by the Food and Drug Administration (FDA) and are not evaluated for safety or efficacy.” That level of disclosure is legally required and factually accurate.

The broader regulatory environment has shifted since mid-2025. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in December 2024. When a branded drug is no longer on the FDA shortage list, the legal authority for compounding pharmacies to produce bulk copies of that drug significantly narrows. The FDA has escalated enforcement against compounded GLP-1 marketing since September 2025, issuing warning letters to multiple telehealth platforms for misbranding violations. In March 2026, Hims & Hers reached a settlement with Novo Nordisk and announced it would stop marketing compounded GLP-1 medications, signaling a major pivot among large-scale telehealth players.

None of this means compounded semaglutide or tirzepatide is currently unavailable or illegal. Patient-specific compounding through 503A pharmacies remains a legal pathway when a prescribing clinician determines a compounded formulation is medically necessary for a specific patient. But the landscape is actively changing, and platforms operating in this space — including MadeMed — face ongoing regulatory scrutiny. Prospective patients should verify current program availability, pricing, and medication sourcing directly on mademed.com before enrolling, as conditions may have changed since this review was written.

The Weight Loss Outcome Claim: What the Research Actually Supports

MadeMed cites an average body weight loss of 15 to 20 percent on its platform. This figure deserves precise context. The 15 to 20 percent body weight reduction range reflects outcomes reported in large-scale clinical trials of FDA-approved semaglutide at the 2.4mg weekly dose — specifically the STEP trial program, which studied brand-name injectable Wegovy in adults with obesity alongside lifestyle intervention. Those trials involved FDA-approved finished drug formulations, conducted in controlled conditions, and enrolled populations meeting specific eligibility criteria.

That clinical literature does not establish that MadeMed's compounded semaglutide products — which are not FDA-approved and have not been evaluated in equivalent trials — will produce the same outcomes. Individual weight-loss results depend on dose, adherence, individual physiology, lifestyle factors, starting weight, and other variables. No telehealth platform can commitment specific outcomes from compounded GLP-1 therapy, and none should. The research supports that semaglutide, when prescribed appropriately and used alongside lifestyle modification under medical supervision, has demonstrated meaningful weight reduction in certain patient populations. Whether any individual qualifies for and responds to GLP-1 therapy is a clinical determination — one made by the licensed providers within Xpedicare, LLC, not by MadeMed.

The MadeMed Intake and Prescribing Process

The enrollment process follows the standard telehealth model used across the compounded GLP-1 market. Prospective patients complete an online medical intake form covering health history, current medications, and weight goals. That information is reviewed by a licensed clinician affiliated with Xpedicare, LLC. The Terms of Use make clear that there is no commitment a prescription will be written — the prescribing decision is entirely at the clinician's discretion based on their professional judgment. MadeMed's Terms of Use also specify that providers do not prescribe DEA-controlled substances.

If a prescription is issued, it is transmitted to AbsoluteRx, MadeMed's licensed pharmacy partner, for fulfillment and direct shipment. Services run on a subscription billing cycle — either 30 or 90 days, depending on the plan selected.

MadeMed's Other Programs: Men's Health, Peptide Therapy, and NAD+

Beyond GLP-1, MadeMed offers a tadalafil-based men's sexual health troche that combines tadalafil with PT-141 and oxytocin. For peptide therapy, the platform offers both injectable and oral sermorelin. Sermorelin is a peptide that may support growth hormone release in certain individuals under medical supervision; it is not approved for anti-aging or general wellness use and requires appropriate clinical evaluation before prescribing. NAD+ therapy is available as both an injectable and a nasal spray.

For a focused review of MadeMed's sermorelin and peptide therapy programs specifically, see our dedicated breakdown: MadeMed Sermorelin and Peptide Therapy: What Patients Should Know. For more on this topic, check out GLPro Supplement Reviews 2026: Is It Legit or Hype?.

Is MadeMed Legitimate? What Independent Verification Tells Us

Based on available information: yes, MadeMed is a real, operating telehealth platform. LegitScript certification indicates the platform has met independent standards for legal compliance and safety in online healthcare operations. The three-entity structure — MadeMed as the platform operator, Xpedicare, LLC as the independent medical group providing clinical services, and AbsoluteRx as the pharmacy partner — is consistent with how compliant telehealth platforms structure the separation between non-clinical services and medical care.

The more useful question for prospective patients is not “is it legitimate?” but “is it the right fit for me?” That depends on your state's availability, your medical history, whether compounded GLP-1 therapy is appropriate for your specific situation, the current regulatory status of the programs you're considering, and how MadeMed's pricing compares at your expected maintenance dose. The answer to those questions requires a conversation with a licensed clinician — one who has reviewed your actual health history. For additional context on how MadeMed compares to other platforms with similar care models, see our reviews of Direct Meds GLP-1 and TeleHealth Med.

What to Verify Before Enrolling with MadeMed

Confirm your state is included in MadeMed's current service area — approximately 40 states as of this writing, but subject to change. Verify current pricing for the specific medication and dose tier you're likely to reach at maintenance, not just the starter price. Read the subscription and cancellation terms in MadeMed's Terms of Use before entering payment information. Ask your prescribing clinician about the pharmacy sourcing for your specific formulation and request a Certificate of Analysis if you want to verify medication quality and ingredient testing. If you are currently taking any medications, including thyroid medications or GLP-1 pathway medications, discuss potential contraindications with a qualified provider before starting. And verify current program availability and pricing directly on mademed.com, as the compounded GLP-1 regulatory environment continues to evolve and information in third-party reviews — including this one — may not reflect the most current program terms.

Frequently Asked Questions

Is MadeMed a legitimate telehealth platform?

MadeMed is operated by IDL Health LLC and holds LegitScript certification. Medical services are provided by Xpedicare, LLC, an independent medical group. All prescribing decisions are made by licensed clinicians — not MadeMed — and medication is dispensed through AbsoluteRx, a licensed pharmacy partner.

How much does MadeMed cost per month?

Published pricing starts at $99 per month for oral semaglutide. NAD+ nasal spray is listed up to $269 per month. An optional MadeMed Club membership at $149 per year provides a $10 monthly discount. Final pricing depends on medication type, dose, and plan structure and should be verified directly on mademed.com before enrollment.

Are MadeMed's GLP-1 medications FDA-approved?

No. MadeMed's Terms of Use state explicitly that compounded medications dispensed through the platform are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This is the regulatory standard for all compounded drugs in the United States.

What states is MadeMed available in?

MadeMed reports availability in approximately 40 states. Certain medications or clinical services may not be available in all states due to state-specific restrictions. Prospective patients should verify their state's availability directly on the platform before completing an intake form.

What medications does MadeMed offer?

MadeMed offers injectable and oral compounded semaglutide, injectable and oral compounded tirzepatide, a tadalafil-based men's wellness troche, injectable and oral sermorelin for peptide therapy, and NAD+ in both injectable and nasal spray formats.

Wellorithm vs Competitors: GLP-1 Telehealth Compared

By TotalCareMedical.com Health Team

Editorial notice: TotalCareMedical.com is an independent health and wellness research publication. This comparison is for educational and informational purposes only and does not constitute medical advice or a recommendation for any specific program. GLP-1 medications are prescription drugs. Compounded medications discussed here have not been reviewed or approved by the FDA for safety, effectiveness, or quality. All pricing and program details are based on publicly available information at the time of publication and are subject to change — verify directly with each platform before enrolling. Some links on this page may be affiliate links; see our disclosure for details.

Clinical Summary: Wellorithm GLP-1 Telehealth Program

Category: Telehealth Platform (Compounded GLP-1 Prescription)
Key Active Ingredients: Compounded semaglutide (injection and oral), compounded tirzepatide (injection and oral)
Price Range: Starting at $147 for semaglutide and $249 for tirzepatide per 28-day billing cycle
Refund Policy: Non-refundable once processed; cancellation available anytime via email support
Evidence Level: Clinical outcomes depend on medication class, dosing, adherence, and lifestyle factors—not platform selection.
Best For: Patients seeking virtual GLP-1 access across 49 states with clinician-guided prescription and compounded medication options.
Caution: Compounded GLP-1 medications have not been FDA-reviewed for safety or effectiveness; verify pricing and program details directly with platform before enrollment.

Comparing GLP-1 Telehealth Programs: What Actually Matters

The compounded GLP-1 telehealth market has expanded significantly heading into 2026, and the number of platforms offering virtual GLP-1 programs has made program comparison increasingly relevant for patients doing due diligence before enrolling. This comparison evaluates Wellorithm against other programs reviewed on this site — TeleHealth Med and SynergyRx GLP-1 Weight Loss — on the dimensions that most affect the patient experience: pricing structure, medication options, pharmacy sourcing, refund policy, clinical intake, and what each program includes.

For the full independent review of Wellorithm's program terms and structure, see our Wellorithm review. For the full index of telehealth platform reviews on this site, visit the telehealth platform reviews hub.

The Comparison Framework

Before comparing platforms, it is worth establishing what the comparison is and is not. This is a comparison of published program terms and structures — not a clinical efficacy comparison. The GLP-1 medications (semaglutide and tirzepatide) are the same active ingredients across all compounded programs. Clinical outcomes depend on the medication class itself, the dose prescribed and titrated, patient adherence, and lifestyle factors — not on which telehealth platform facilitated the prescription. Choosing the right platform is about access, cost structure, clinical process quality, and consumer protection terms — not about the medication performing differently based on where you enrolled.

Wellorithm: Program Summary

Wellorithm is a telehealth platform connecting patients with licensed clinicians for compounded GLP-1 evaluation. The program offers compounded semaglutide (injection and oral dissolving tablets) and compounded tirzepatide (injection and oral dissolving tablets). All medications are compounded formulations — not FDA-approved brand-name products. According to the official website, published starting prices are $147 for compounded semaglutide and $249 for compounded tirzepatide. Membership is billed on a 28-day recurring cycle. Payments are non-refundable once processed; cancellation is available at any time by contacting support via email. The platform serves 49 states (Louisiana excluded). Support is available 24/7 at +1 (877) 402-6778. The program operates on a cash-pay basis — insurance is generally not billed directly.

TeleHealth Med: Program Summary

TeleHealth Med is a compounded GLP-1 telehealth program that connects patients with licensed providers for online consultation, prescription, and home medication delivery through licensed U.S. pharmacies. The program's published starting price is $147. Its model follows the same three-entity structure as Wellorithm: platform, independent licensed clinicians, and pharmacy partners. The program is described as offering personalized treatment plans, 24/7 support, and flexible video consultation scheduling. As with Wellorithm, compounded medications offered through TeleHealth Med have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

SynergyRx GLP-1 Weight Loss: Program Summary

SynergyRx GLP-1 Weight Loss distinguishes itself from Wellorithm and TeleHealth Med primarily by offering both compounded GLP-1 options and FDA-approved brand-name medications — Wegovy, Ozempic, and Mounjaro — for patients for whom brand-name products are clinically appropriate. Published starting prices for SynergyRx are higher across the compounded tier: compounded semaglutide injection from $199, compounded tirzepatide injection from $349, oral compounded semaglutide from $299, oral compounded tirzepatide from $399. Brand-name options start at $499 (Ozempic) or $947 (Wegovy, Mounjaro). The program names its medical team (Lion MD, led by Dr. Ana Lisa Carr MD and Dr. Kelly Tenbrink MD) and pharmacy partners (Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx), providing a level of sourcing transparency that patients evaluating compounded medication programs may find relevant. The program is available in all 50 states per its published FAQ.

Head-to-Head: Key Comparison Dimensions

Pricing for compounded semaglutide: Wellorithm from $147, TeleHealth Med from $147, SynergyRx from $199. All are starting prices subject to dose and plan. Wellorithm and TeleHealth Med are at price parity on the published entry price for this medication.

Pricing for compounded tirzepatide: Wellorithm from $249, SynergyRx from $349. TeleHealth Med's tirzepatide pricing was not separately published in available materials at the time of this review — verify directly with the platform.

Medication scope: Wellorithm and TeleHealth Med offer compounded formulations only. SynergyRx offers both compounded and FDA-approved brand-name options, making it the only platform of the three with a pathway to Wegovy, Ozempic, or Mounjaro for patients who qualify and for whom the cost is accessible.

Pharmacy sourcing transparency: SynergyRx names its pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx). Wellorithm refers to “trusted U.S. pharmacies” without naming partners in publicly available materials. TeleHealth Med similarly references licensed U.S. pharmacy partners. For patients who want to independently verify the compounding compliance status of the dispensing pharmacy, named partners provide a research pathway that unnamed references do not.

Refund terms: Wellorithm's published terms state payments are non-refundable once processed. SynergyRx and TeleHealth Med refund policies should be verified directly with each platform — terms vary across the category and are subject to change.

State coverage: Wellorithm serves 49 states (Louisiana excluded). SynergyRx is published as available in all 50 states. Verify your state's current availability with each platform before enrolling.

Clinical intake depth: All three programs require a digital health questionnaire and clinician evaluation before prescribing. SynergyRx's published clinical description is the most detailed of the three — it specifies eligibility criteria (BMI ≥30 or ≥27 with comorbidity), names the medical team, and details the titration approach. Wellorithm's published intake description (2-minute quiz) is less detailed about clinical evaluation depth — this is worth confirming directly with the platform for patients who want to understand the thoroughness of the screening process. For a deeper dive, see Oak Longevity Review: Is the GLP-1 Pricing Real?.

How to Choose: Questions Worth Asking

The right program is the one that fits your health profile, budget, state, and preferences for medication type and clinical process depth. These are the questions worth asking before enrolling in any of these programs.

Do you want access to FDA-approved brand-name medications if compounded options become unavailable or if your clinician recommends them? If yes, SynergyRx is the only platform of the three with that pathway published. Is price the primary constraint? Wellorithm and TeleHealth Med offer the lowest published starting prices in this comparison. Do you want to know which pharmacy will dispense your medication so you can independently verify its compounding compliance status? SynergyRx provides named pharmacy partners. Is state availability a factor — are you in Louisiana? Only SynergyRx publishes 50-state availability among the three platforms reviewed here. What is the refund policy if you are not approved for a prescription or decide not to proceed after enrollment? This should be confirmed in writing before providing payment information to any platform.

Frequently Asked Questions

How does Wellorithm compare to other GLP-1 telehealth programs on price? Wellorithm's published starting prices — $147 for compounded semaglutide, $249 for compounded tirzepatide — are at the lower end of published pricing in the compounded GLP-1 telehealth category. Actual costs depend on dosage and plan. Comparable platforms in this category publish semaglutide starting prices ranging from $147 to $350 or higher, with tirzepatide priced above semaglutide across the category. Price comparisons should account for what is included: consultation fees, monitoring, and pharmacy sourcing vary by platform.

What makes Wellorithm different from SynergyRx? SynergyRx offers both compounded and FDA-approved brand-name GLP-1 options, including Wegovy, Ozempic, and Mounjaro, with named pharmacy partners and a named medical team. Wellorithm focuses on compounded formulations only, at lower published starting prices, with 24/7 support access. Both are cash-pay programs. The right choice depends on whether brand-name medication access matters to you and what total cost structure fits your situation.

Which GLP-1 telehealth platform is best? No single platform is universally best. The right program depends on individual health profile, budget, medication preference (compounded vs. brand-name), state availability, and the clinical intake process. The most important evaluation dimensions are: whether the clinician evaluation is thorough, what pharmacy dispenses the medication and what its compounding compliance status is, what follow-up monitoring is included, and what the refund and cancellation terms are.

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

Wellorithm Side Effects: Gastrointestinal Effects and Titration

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important notice: This article is for educational and informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that require evaluation, prescription, and monitoring by a licensed healthcare professional. Compounded medications discussed here have not been reviewed or approved by the FDA for safety, effectiveness, or quality. All medical decisions — including whether to start, continue, or stop any medication — must be made in consultation with a licensed clinician. If you experience a severe adverse reaction, seek immediate medical attention.

Clinical Summary: GLP-1 Receptor Agonist Side Effects

Topic: Educational overview of GLP-1 medication side effects and safety monitoring
Category: Telehealth program (Wellorithm) providing access to compounded GLP-1 medications
Key Active Ingredients: Compounded semaglutide and compounded tirzepatide (GLP-1 receptor agonists)
Price Range: Not disclosed
Evidence Level: Moderate — based on peer-reviewed clinical trial data (STEP and SURMOUNT trials) and FDA-registered, GMP-certified labeling
Primary Side Effects: Gastrointestinal effects (nausea in ~44% of semaglutide users vs. 16% placebo), vomiting, and diarrhea; typically diminish after titration period
Best For: Patients seeking informed understanding of GLP-1 side effect profiles before enrollment in telehealth weight management programs
Caution: Compounded formulations lack FDA review; requires licensed clinician evaluation, prescription, and ongoing monitoring; contraindications and drug interactions must be assessed individually by healthcare provider

GLP-1 Side Effects: What This Article Covers

Wellorithm connects eligible patients with licensed clinicians for evaluation and, when medically appropriate, access to compounded GLP-1 medications — primarily compounded semaglutide and compounded tirzepatide. Before enrolling in any GLP-1 program, understanding the side effect profile is a basic prerequisite for informed consent. This article covers what the peer-reviewed clinical literature and FDA-registered, GMP-certified labeling document about GLP-1 receptor agonist side effects, how they are typically managed, the contraindications that make these medications inappropriate for certain patients, and the monitoring steps that responsible programs should include.

This is not a Wellorithm-specific safety file. There is no published independent clinical safety data specific to Wellorithm's compounded formulations. The safety information here is drawn from the peer-reviewed literature and FDA labeling for the GLP-1 drug class — semaglutide and tirzepatide — which is the relevant clinical basis for evaluating this category of medication. For the full review of Wellorithm's program and pricing terms, see our Wellorithm review. For a breakdown of the semaglutide mechanism, see our Wellorithm semaglutide breakdown.

Common Side Effects: Gastrointestinal

The most frequently reported side effects of GLP-1 receptor agonists are gastrointestinal, and this pattern is consistent across the STEP trial data for semaglutide and the SURMOUNT trial data for tirzepatide published in peer-reviewed literature. These effects are primarily a consequence of the mechanism itself — slowing gastric emptying and altering gut motility produces predictable GI effects in a meaningful proportion of patients.

Nausea is the most commonly reported side effect. In the STEP 1 trial data published in the New England Journal of Medicine, nausea was reported in approximately 44% of semaglutide participants compared with approximately 16% of placebo participants during the trial. It is most common in the early weeks of treatment and typically diminishes with continued use, particularly after the initial titration period stabilizes. Eating smaller meals, eating slowly, and avoiding high-fat or highly spiced foods are commonly recommended dietary strategies during early treatment.

Vomiting and diarrhea are also reported more frequently in GLP-1 treatment groups than in placebo groups in clinical trials. Like nausea, these effects are most common during the early treatment period and during dose escalation steps. They generally diminish over time as the gastrointestinal system adjusts.

Constipation is the GI side effect that patients often find most persistent. Unlike nausea and diarrhea, which tend to peak early and resolve, constipation may persist throughout the treatment period for some patients. Adequate hydration and dietary fiber are the primary management strategies; patients experiencing significant constipation should discuss management options with their prescribing clinician.

Abdominal discomfort, bloating, and reflux are also reported. These effects are related to slower gastric emptying and may be exacerbated by meal size or composition.

Dose Titration: Why It Matters for Tolerability

The standard approach to managing GLP-1 gastrointestinal side effects is gradual dose titration — starting at the lowest dose and increasing at defined intervals rather than starting at the therapeutic dose. The FDA-approved Wegovy dosing schedule, for example, begins at 0.25 mg once weekly and increases in steps every four weeks before reaching the maintenance dose of 2.4 mg. This stepwise approach reflects clinical evidence that slower titration reduces the frequency and severity of GI side effects.

In telehealth programs, the prescribing clinician determines the titration schedule based on the patient's response and tolerability. Patients experiencing severe or persistent side effects should contact their provider — dose adjustment or a slower titration schedule may be appropriate. Patients should not self-adjust dosing without clinician guidance.

Serious Risks: What the FDA Labeling Documents

Beyond the common gastrointestinal side effects, FDA-registered, GMP-certified labeling for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) documents several more serious potential risks that every patient should understand before starting treatment.

Thyroid C-cell tumor risk (boxed warning): Semaglutide and tirzepatide carry an FDA boxed warning based on animal study findings showing dose-dependent increases in thyroid C-cell tumors. This risk has not been confirmed in humans and the clinical relevance to human patients is uncertain; however, both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients with relevant family history must disclose this during the intake evaluation — these conditions are absolute contraindications.

Pancreatitis: GLP-1 receptor agonists have been associated with acute pancreatitis in clinical reports. FDA labeling for semaglutide and tirzepatide advises discontinuing the medication promptly if pancreatitis is suspected and not restarting it if pancreatitis is confirmed. Patients with a history of pancreatitis should discuss this with a clinician before initiating GLP-1 therapy.

Gallbladder disease: An increased risk of gallbladder-related adverse events, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation), has been reported in clinical trials of GLP-1 medications. The mechanism may relate to altered bile composition and gallbladder contractility. Patients with known gallbladder disease or symptoms of abdominal pain should discuss this with their clinician.

Hypoglycemia: GLP-1 medications stimulate insulin secretion in a glucose-dependent manner, which generally makes hypoglycemia less likely than with some other diabetes medications. However, patients taking concomitant insulin or insulin secretagogues (sulfonylureas) are at increased risk for hypoglycemia when adding a GLP-1 medication. Medication interactions must be disclosed during the intake evaluation.

Heart rate increase: GLP-1 receptor agonists have been associated with a modest increase in resting heart rate. Clinical trials have not shown cardiovascular harm from this effect — in fact, some GLP-1 medications have demonstrated cardiovascular benefit in specific patient populations in long-term trials. However, patients with pre-existing tachycardia or relevant cardiovascular conditions should discuss this with their clinician.

Contraindications: Who Should Not Use GLP-1 Medications

Per FDA-registered, GMP-certified labeling for semaglutide and tirzepatide, the following are absolute contraindications:

Personal or family history of medullary thyroid carcinoma. Personal or family history of multiple endocrine neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or tirzepatide, respectively, or any component of the formulation.

These are hard stops. Patients with any of these conditions are not candidates for GLP-1 therapy and should not enroll in any program offering these medications. Accurate disclosure during the intake questionnaire is the mechanism through which the prescribing clinician identifies and screens for these contraindications. Incomplete disclosure creates clinical risk.

Additionally, GLP-1 medications are not approved for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

What Responsible Monitoring Looks Like

GLP-1 therapy is not a one-time prescription interaction. Responsible programs include follow-up monitoring to assess tolerability, track weight changes, manage side effects, and adjust dosing when appropriate. Patients evaluating any telehealth GLP-1 program — including Wellorithm — should confirm what ongoing monitoring is included in the program pricing and how to reach a provider if side effects emerge between scheduled consultations.

Wellorithm's published program description includes 24/7 support access by phone at +1 (877) 402-6778. Patients should confirm the process for reporting adverse effects and accessing clinical review if symptoms emerge.

Muscle Loss: A Consideration for Long-Term Programs

One consideration that has received increasing attention in discussions of GLP-1 weight loss programs is lean body mass loss. Clinical trial data suggest that a portion of weight lost during GLP-1 therapy may include lean muscle mass, not only fat tissue. The proportion of lean mass loss varies across individuals and studies. In clinical trial settings, this concern has been addressed through recommendations for adequate protein intake and resistance exercise during the treatment period. Patients in telehealth programs should discuss protein targets and exercise recommendations with their clinician at the outset of treatment — this is an area where behavioral guidance alongside medication management matters.

For More Information

For the complete program review including pricing and refund terms, see the Wellorithm review. For the full index of GLP-1 telehealth platform reviews on this site, see our weight management research hub.

Frequently Asked Questions

What are the most common side effects of GLP-1 medications like those offered through Wellorithm? The most common side effects reported in clinical trials of GLP-1 receptor agonists including semaglutide and tirzepatide are gastrointestinal in nature: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are most common during the early weeks of treatment and during dose increases. They often diminish as the body adjusts to the medication.

Are there serious risks associated with semaglutide or tirzepatide? Rare but serious risks identified in clinical research and FDA-registered, GMP-certified labeling include pancreatitis, gallbladder disease, and a boxed warning for a risk of thyroid C-cell tumors observed in animal studies. The thyroid tumor risk has not been confirmed in humans, but semaglutide and tirzepatide are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. All risks should be discussed with a licensed clinician before starting treatment.

How are GLP-1 side effects managed? Common gastrointestinal side effects are typically managed through gradual dose titration — starting at a low dose and increasing slowly — along with dietary adjustments such as eating smaller meals, avoiding high-fat or high-sugar foods, and staying hydrated. If side effects are severe or persistent, the prescribing clinician may adjust the dosing schedule or evaluate whether the medication is appropriate to continue.

Who should not take GLP-1 medications? Per FDA-registered, GMP-certified labeling for semaglutide and tirzepatide, these medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. They should be used with caution in patients with a history of pancreatitis. Other contraindications and precautions exist — a complete medical evaluation by a licensed clinician is required before prescribing.

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.

Wellorithm Semaglutide: Compounded GLP-1 Breakdown

By TotalCareMedical.com Health Team

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important notice: This article is for educational and informational purposes only and does not constitute medical advice. Semaglutide is a prescription medication that must be evaluated, prescribed, and monitored by a licensed healthcare professional. Compounded semaglutide has not been reviewed or approved by the FDA for safety, effectiveness, or quality. Eligibility for any prescription program is determined solely by a licensed clinician. Always consult your healthcare provider before starting any medication or weight management program.

Clinical Summary: Wellorithm Compounded Semaglutide

Category: Telehealth Platform for Prescription GLP-1 Medications
Key Active Ingredients: Semaglutide (compounded formulation available in injectable and oral dissolving tablet forms)
Price Range: Not disclosed
Evidence Level: Compounded semaglutide has not undergone FDA approval for safety, effectiveness, or quality; clinical efficacy data applies to FDA-approved semaglutide products (Wegovy, Ozempic).
Best For: Eligible patients with obesity/overweight conditions or type 2 diabetes who qualify for prescription GLP-1 therapy through licensed clinician evaluation.
Caution: Compounded medications are not FDA-reviewed; manufactured under state pharmacy regulations with different standards than approved drugs; requires licensed healthcare provider evaluation and monitoring; discuss risks versus FDA-approved alternatives with prescribing clinician.

What Wellorithm Offers: The Semaglutide Pathway

Wellorithm is a telehealth platform that connects eligible patients with licensed clinicians for evaluation and, when medically appropriate, access to compounded GLP-1 medications. Among the options the platform describes is compounded semaglutide — available in both injectable and oral dissolving tablet formulations, according to the official Wellorithm website.

This article examines what compounded semaglutide actually is, how the medication class works mechanistically, what the clinical trial literature supports about outcomes, how the compounding regulatory framework applies to platforms like Wellorithm in 2026, and what to understand before pursuing this type of program. For a full review of Wellorithm's program structure and pricing terms, see our Wellorithm review. For a comparison of safety considerations, see our Wellorithm side effects breakdown.

Compounded vs. FDA-Approved: The Distinction That Matters

Semaglutide is the active ingredient in two FDA-approved brand-name products: Wegovy, approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and Ozempic, approved for type 2 diabetes management with cardiovascular risk reduction indications. Both Wegovy and Ozempic have undergone comprehensive FDA review for safety, efficacy, and manufacturing quality as finished drug products.

Compounded semaglutide — the formulation available through platforms like Wellorithm — is prepared by a licensed compounding pharmacy based on an individual prescription. The finished compounded product has not undergone the same FDA approval process. As Wellorithm's own website acknowledges, compounded medications have not been reviewed or approved by the FDA for safety, effectiveness, or quality.

This distinction is not a minor regulatory technicality. FDA approval of a finished drug product involves manufacturing quality standards, potency verification, stability testing, and post-market surveillance requirements that do not apply to compounded preparations. Compounded medications are prepared under state pharmacy regulations and applicable federal compounding law, which sets different standards than the FDA drug approval pathway. Patients making decisions about compounded versus brand-name GLP-1 access should understand this difference clearly and discuss it with their prescribing clinician.

The 2026 Regulatory Landscape for Compounded GLP-1 Medications

The availability of compounded GLP-1 medications from telehealth platforms has been directly tied to FDA drug shortage designations, and this regulatory context has been actively evolving for both semaglutide and tirzepatide.

Federal compounding law restricts the production of compounded drugs that are essentially copies of commercially available FDA-approved products. During periods when the FDA has designated semaglutide or tirzepatide as being in shortage, enforcement discretion guidance has allowed certain compounding pharmacies to produce these medications under specific conditions. When the FDA's shortage designation changes — indicating the brand-name version is considered adequately available — that enforcement discretion may no longer apply.

Patients considering any compounded GLP-1 program in 2026 should confirm directly with the telehealth platform whether the specific compounded medication is currently available and under what regulatory framework it is being produced. This is not a static fact — it can change based on FDA actions that are independent of any individual platform's operations.

How Semaglutide Works: The GLP-1 Mechanism

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the GLP-1 hormone that is naturally released by the gastrointestinal tract in response to food intake. This mechanism produces several overlapping physiological effects relevant to weight management.

In the central nervous system, GLP-1 receptors are found in hypothalamic regions involved in appetite regulation and satiety. Activation of these receptors reduces appetite drive and increases the perception of fullness, which may support reduced caloric intake in patients who respond to the medication. In the gastrointestinal tract, semaglutide slows gastric emptying — the rate at which food moves from the stomach to the small intestine — which extends post-meal satiety. On the metabolic side, GLP-1 receptor activation stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon secretion, contributing to improved glycemic regulation in patients with insulin resistance or type 2 diabetes.

These mechanisms act together to reduce appetite, slow digestion, and improve glucose metabolism — all relevant to chronic weight management when the medication is prescribed and monitored appropriately.

What the Clinical Evidence Shows

The clinical evidence base for semaglutide in weight management is grounded in the STEP (Semaglutide Treatment Effect in People with Obesity) trial program, a series of Phase 3 randomized controlled trials published in peer-reviewed journals including the New England Journal of Medicine. The STEP trials examined semaglutide 2.4 mg administered once weekly — the dosing used in the Wegovy FDA-approved indication for weight management.

STEP 1, published in the New England Journal of Medicine in 2021, reported that in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition and without type 2 diabetes, participants receiving semaglutide alongside lifestyle intervention achieved a mean weight reduction of approximately 15% of baseline body weight over 68 weeks in the clinical trial population. The placebo group achieved approximately 2.4% weight reduction over the same period. These are clinical trial findings — individual outcomes in real-world settings vary based on metabolic factors, adherence, lifestyle changes, and other variables. Trial results do not constitute a commitment of outcomes for any individual patient or through any specific telehealth platform.

Compounded semaglutide formulations available through telehealth platforms use semaglutide as the active ingredient, but the compounded products themselves have not been studied in the same clinical trial infrastructure as the FDA-approved finished drugs. The clinical literature on semaglutide's effects pertains to the FDA-approved formulations studied in those trials, not to compounded versions specifically.

Wellorithm's Semaglutide Pricing: Verified Terms

According to the official Wellorithm website, compounded semaglutide starts at $147 per cycle. Membership fees are billed on a recurring 28-day basis. These are starting prices — the actual cost depends on the dosage level prescribed and the specific plan selected. Wellorithm's program operates on a cash-pay basis. Insurance is generally not billed directly; reimbursement eligibility depends on your individual plan.

Published refund policy, per Wellorithm's terms: membership payments are non-refundable once processed. Cancellation is available at any time by contacting the support team via email. Always verify current pricing and terms directly on the official Wellorithm website before enrolling — pricing is subject to change.

For a side-by-side comparison of how Wellorithm's semaglutide pricing compares to other platforms in this category, see our Wellorithm vs. competitors review.

Semaglutide Dosing: How Titration Works

GLP-1 medications including semaglutide are typically initiated at a low dose and gradually increased — a process called titration — to minimize gastrointestinal side effects such as nausea, which are most common during early treatment and dose increases. The FDA-approved Wegovy dosing schedule starts at 0.25 mg once weekly for four weeks, with increases at four-week intervals up to the maintenance dose of 2.4 mg once weekly.

Compounded semaglutide programs may follow similar titration frameworks, though the specific protocol is determined by the prescribing clinician based on the individual patient's response, tolerability, and treatment goals. Dose adjustments require clinician involvement — patients should not self-adjust dosing without provider guidance.

Who Is a Candidate for Semaglutide-Based Weight Management

The published clinical guidelines for GLP-1 prescription weight management typically identify eligibility based on BMI: 30 or higher for obesity classification, or 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. These thresholds are reflected in FDA-registered, GMP-certified labeling and are the standard framework used by clinicians evaluating patients for GLP-1 therapy.

Certain medical conditions may disqualify a patient from semaglutide regardless of BMI. These include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — contraindications listed in FDA-registered, GMP-certified labeling for semaglutide products. Pancreatitis history, certain gallbladder conditions, and specific medication interactions are also factors a clinician will evaluate. The intake disclosure process is the mechanism through which these factors are assessed; accurate and complete disclosure is essential.

Oral vs. Injectable: What the Evidence Supports

Wellorithm lists both injectable and oral dissolving tablet formulations of compounded semaglutide. The oral route is a meaningful consideration for patients who prefer not to self-inject, and oral semaglutide is also the basis of Rybelsus, an FDA-approved oral semaglutide formulation for type 2 diabetes management — though Rybelsus is not the same as compounded oral semaglutide tablets and is not FDA-approved for weight management specifically.

The bioavailability of oral semaglutide differs from injectable semaglutide, and dosing protocols differ accordingly. Whether an oral compounded formulation achieves comparable clinical outcomes to injectable formulations in real-world telehealth settings is a question the prescribing clinician should address during the consultation — it is not answered by the current peer-reviewed literature on injectable semaglutide alone.

Frequently Asked Questions

What is compounded semaglutide? Compounded semaglutide is a formulation of semaglutide — the active ingredient in FDA-approved products Wegovy and Ozempic — prepared by a licensed compounding pharmacy based on an individual prescription. The compounded product itself has not been reviewed or approved by the FDA for safety, effectiveness, or quality. A licensed clinician must evaluate whether it is appropriate for each patient.

Is compounded semaglutide the same as Wegovy or Ozempic? No. Wegovy and Ozempic are FDA-approved brand-name finished drug products that have undergone rigorous FDA review for safety, efficacy, and manufacturing quality. Compounded semaglutide is prepared by a licensed compounding pharmacy and has not undergone the same FDA approval process. The active ingredient is semaglutide in both cases, but the finished products are legally and regulatorily distinct.

What starting price does Wellorithm publish for compounded semaglutide? According to the official Wellorithm website, compounded semaglutide starts at $147. This is a starting price — actual cost depends on dosage and plan selected. Pricing is subject to change; verify directly on the official website before enrolling.

How does semaglutide support weight management? Semaglutide is a GLP-1 receptor agonist that mimics the GLP-1 hormone involved in appetite regulation, satiety signaling, gastric emptying, and insulin secretion. Clinical trial data published in peer-reviewed literature — including the STEP trials — demonstrated meaningful weight reduction in adults with obesity when semaglutide was used alongside lifestyle interventions. Individual outcomes vary and are not designed to deliver.

What is the regulatory context for compounded GLP-1 medications in 2026? The availability of compounded GLP-1 medications has been tied to FDA drug shortage designations. Federal compounding regulations restrict the production of compounded drugs that are essentially copies of commercially available FDA-approved products, with enforcement discretion tied to shortage status. This has been an active and evolving area for semaglutide and tirzepatide. Patients should confirm current availability directly with any telehealth platform before enrolling.